Positive Impacts of a Four-Week Neuro-Meditation Program on Cognitive Function in Post-Acute Sequelae of Covid-19 Patients

A Randomized Controlled Trial

Bibliographic Data

ID15512948
AuthorsChristophe Hausswirth (Laboratoire Motricité Humaine Éducation Sport Santé, corresponding author), Cyril Schmit (Fondation Sophia Antipolis), Yann Rougier (WHealth Found, 06270 Villeneuve-Loubet, France), Alexandre Coste (0000-0002-4497-6473, Fondation Sophia Antipolis)
Year2023
Volume20
Issue2
Pages1361-1361
Publication date2023-01-11
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph20021361
PMID36674117
OpenAlexW4315652356
LanguageEN
Citations received3
References cited47

Study objective: Long COVID patients can experience high levels of impairment in their cognitive function and mental health. Using a parallel randomized control trial, we evaluated the effectiveness of a neuro-meditation program to reduce cognitive impairment in patients with long COVID. Methods: A total of 34 patients with long COVID were randomized to an intervention group (G-Int; n = 17) or a control group (G-Con; n = 17) and 15 healthy participants were constitutive of a normative group (G-Nor). The intervention consisted of ten 30-min sessions of Rebalance® over a period of five weeks. Each session included sound therapy and coach-guided meditation associated with light stimulations (i.e., chromotherapy). Primary outcomes were performance on five computerized cognitive tasks (choice response time, pattern comparison, Simon, pursuit rotor task, and Corsi block-tapping task), mental and physical fatigue (Chalder fatigue scale), perceived stress (perceived stress scale) and mood (profiles of mood states). Secondary outcomes were anxiety and depressive symptoms (hospital anxiety and depression scale), muscular pain, joint pain, and headaches using visual analog scales (VAS) as well as sleep quality (Spiegel sleep questionnaire). Assessments were conducted at baseline and at 1−2 and 7−8 days of follow-up. Results: Compared to healthy subjects, long COVID patients showed significant differences at baseline on all the self-report questionnaires, and a Rebalance® program improved all the subjective reports, as well as cognitive performances, especially on reaction time-based tasks. In particular, only the G-Int group revealed shortened reaction times in the choice reaction time (RTbaseline = 593 ± 121 ms vs. RTpost2 = 521 ± 86 ms, p < 0.001), Simon (RTbaseline = 539 ± 123 ms vs. RTpost2 = 494 ± 134 ms, p < 0.01), and pattern comparison tasks (RTbaseline = 1244 ± 315 ms vs. RTpost2 = 1079 ± 213 ms, p < 0.001). Conclusions) Initial evidence suggests that neuro-meditation reduces cognitive impairment and improves physical and mental fatigue, muscle and joint pain, symptoms of depression and anxiety, mood disturbances as well as sleep quality. The Rebalance® program hence constitutes a promising non-pharmacological intervention for the treatment of long-term psychological/cognitive outcomes of COVID-19

Anxiety · Cognition · Mood · Perceived Stress Scale · Physical therapy · Psychiatry · Randomized controlled trial · Visual analogue scale · Clinical Psychology · COVID-19 and Mental Health · Intensive Care Unit Cognitive Disorders · Long-Term Effects of COVID-19 · Medicine · Psychology · Internal Medicine

Tools

Open DOIOpen Access